Table 2

Demographic and clinical characteristics of patients with IBS with and without intestinal spirochetosis

No spirochetosis*Spirochetosis; all†Spirochetosis; mucus-associated‡Spirochetosis; membrane-associated‡
No of participants361459
No of females (%)27 (75)10 (71)4 (80)6 (67)
Median age (p25–p75)§31 (24–42)28 (24–31)29 (28–45)26 (23–30)
Median duration, years (p25–p75)§15 (7–24)10 (4–13)10 (7–18)10 (1–10)
No of IBS-D (%)11/36 (31)8/14 (57)2/5 (40)6/9 (67)
No of IBS-C (%)11/36 (31)2/14 (14)2/5 (40)0/9 (0)
No of IBS-M (%)11/36 (31)2/14 (14)0/5 (0)2/9 (22)
No of IBS-U (%)3/36 (8)2/14 (14)1/5 (20)1/9 (11)
Median IBS-SSS (p25–p75)§318 (231–365)280 (220–354)277 (203–282)336 (233–355)
Median extracolonic SSS (p25–p75)§189 (123–271)125 (75–175)202 (174–244)75 (73–106)
Median OATT5 (p25–p75)§1.3 (0.8–2.4)1.1 (0.8–1.8)1.9 (1.1–2.6)1.0 (0.8–1.4)
Median rectal pain threshold, mm Hg (p25–p75)§28 (20–28)28 (20–32)32 (27–37)20 (20–32)
  • *Patients with IBS negative for Brachyspira according to at least two different methods, with no positive results.

  • †Patients with IBS positive for Brachyspira according to at least two methods.

  • ‡The stratification of mucus-associated and membrane-associated spirochetosis was based on immunofluorescence analysis of biopsy sections.

  • §p25, 25th percentile; p75, 75th percentile.

  • IBS-C, IBS with constipation; IBS-D, IBS with diarrhoea ; IBS-M, IBS with mixed bowel habits; IBS-U, unsubtyped IBS without diarrhoea or constipation; OATT, oro-anal transit time (days); SSS, Severity Scoring System.